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Mutations in the gene encoding tripartite motif protein 32 (TRIM32) cause two seemingly diverse diseases:
limb-girdle muscular dystrophy type 2H (LGMD2H) or sarcotubular myopathy (STM) and Bardet–Biedl
syndrome type 11(BBS11). Although TRIM32 is involved in protein ubiquitination, its substrates and the
molecular consequences of disease-causing mutations are poorly understood. In this paper, we show that
TRIM32 is a widely expressed ubiquitin ligase that is localized to the Z-line in skeletal muscle. Using the
yeast two-hybrid system, we found that TRIM32 binds and ubiquitinates dysbindin, a protein implicated in
the genetic aetiology of schizophrenia, augmenting its degradation. Small-interfering RNA-mediated
knock-down of TRIM32 in myoblasts resulted in elevated levels of dysbindin. Importantly, the LGMD2H/
STM-associated TRIM32 mutations, D487N and R394H impair ubiquitin ligase activity towards dysbindin
and were mislocalized in heterologous cells. These mutants were able to self-associate and also co-immuno-
precipitated with wild-type TRIM32 in transfected cells. Furthermore, the D487N mutant could bind to both
dysbindin and its E2 enzyme but was defective in monoubiquitination. In contrast, the BBS11 mutant
P130S did not show any biochemical differences compared with the wild-type protein. Our data identify
TRIM32 as a regulator of dysbindin and demonstrate that the LGMD2H/STM mutations may impair substrate
ubiquitination.
INTRODUCTION
The ubiquitin–proteasome system (UPS) is the major pathway
responsible for protein degradation in eukaryotic cells (1).
Lysine residues within target proteins are modified by covalent
attachment of the 8.5 kDa regulatory protein ubiquitin through
the sequential action of three ubiquitin ligases: E1, E2 and E3
(2). Ubiquitin can itself serve as an acceptor for further rounds
of ubiquitination, forming a polyubiquitin chain. Lysine 48
(K48)-linked polyubiquitin chains are recognized by the protea-
some, which rapidly degrades the modified protein. Through its
ability to selectively target proteins for destruction, the UPS is
involved in all aspects of eukaryotic cell biology and has an
important role in degrading misfolded proteins (3).
In humans, there are 68 members of the TRIM protein family
that contain the eponymous tripartite motif domains: RING,
BBOX and a coiled-coil (4,5). Many TRIM proteins have
additional and variable C-terminal domains, including the SP1a
and the RYanodine receptor (SPRY), NCL-1, HT2A and LIN-
41 (NHL) and plant homeodomain (PHD) domains (4). Despite
the prevalence of TRIM genes in the genome, most members
of this protein family have poorly defined biological functions.
A small number of TRIM family members have been shown to
possess E3 ubiquitin ligase activity and have been implicated in
different diseases states, such as cancer (6–8), retroviral restric-
tion (5) and inherited genetic disease (9–12), indicating that they
have important cellular roles.
In 2002, Frosk et al. (9) described a mutation, D487N, in the
gene encoding tripartite motif protein 32 (TRIM32) as the
SPRY cause of limb-girdle muscular dystrophy type 2H
(LGMD2H). LGMD2H is a mild, autosomal recessive muscle
disease that was originally described in the Manitoba Hutterite
population (13). Historically, these patients were described as
having sarcotubular myopathy (STM). Clinically, the disease is
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characterized by moderately elevated serum creatine kinase
levels, slowly progressive weakness and wasting of the proximal
limb musculature and a relatively late onset in the second or third
decade of life. Similarly, Mu¨ller-Felber et al. (14) described two
German patients with a congenital, non-progressive muscle
disease with segmental vacuolation of some muscle fibres diag-
nosed as STM. The muscle biopsies of these patients showed evi-
dence of Z-line streaming, dilation of the sarcotubular system,
autophagic double-membraned vacuoles and an increased
number of centrally located myonuclei. Although STM has an
earlier onset and is clinically more severe than LGMD2H, the
same D487N mutation has been shown to cause both disorders
suggesting that the clinical phenotype is heterogeneous (15).
This mutation resides in the third NHL repeat of TRIM32 (9).
These repeats are thought to fold into a six-bladed b-propeller
structure (16,17). Studies on proteins such as Brat and malin
have shown that the NHL repeats mediate protein–protein inter-
actions (16–18). Three additional mutations in the first (R394H),
fourth (T520TfsX13) and fifth (D588del) NHL repeats of
TRIM32 were also found to cause LGMD2H in non-Hutterite
populations (19). Interestingly, this study also identified one
patient with LGMD2H attributable to heterozygous mutation
R394H/þ in the TRIM32 gene (19). Recently, a mouse model
of LGMD2H/STM has been described that recapitulates many
of the features in the LGMD2H/STM in humans (20).
However, in addition to muscular dystrophy, these mice also
have evidence of neurological involvement that may contribute
to some of the myopathic changes observed in their muscles.
These changes have been attributed in part to decreased levels
of neurofilaments in Trim32 knockout mice concomitant with a
reduction in the diameter of myelinated motor axons (20).
In contrast, a missense mutation P130S, in the BBOX domain
of TRIM32, causes Bardet–Biedl syndrome type 11 (BBS11)
(21). BBS is a complex condition associated with obesity,
retinal degeneration, genito-urinary tract malformations and
cognitive impairment (22). Furthermore, BBS appears to be
associated with an increased incidence of psychiatric and be-
havioural abnormalities (23,24). In mammals, the majority of
the BBS proteins participate in the formation of the primary
cilium and exist in a 450 kDa multiprotein complex, termed
the BBSsome (25). In addition to their role in ciliogenesis,
BBS proteins participate in a number of signalling pathways
and may have a more general role in vesicular trafficking and
movement of intracellular organelles such as melanosomes
(26). Intriguingly, no muscle abnormality is found in BBS
patients, suggesting different aspects of TRIM32 function are
disrupted by the LGMD2H mutations.
Although TRIM32 is thought to be involved in protein ubiqui-
tination, its precise physiological role in muscle is unknown
(27). A recent report investigating the role of TRIM32 in muscle
demonstrated that TRIM32 binds to myosin IIA and ubiquitinates
actin in vitro (27). This study also concluded that TRIM32–
D487N behaved like the wild-type protein with respect to its
ability to monoubiquitinate actin. In a separate study, Saccone
et al. (19) have reported that the D487N mutation impairs both self-
association and E2-binding in yeast. Paradoxically, this defect
would be predicted to drastically impair substrate ubiquitination.
In addition to its role in genetic disease, TRIM32 is up-regulated
in epidermal carcinogenesis, where it is thought to increase kera-
tinocyte survival by blocking ultraviolet light B (UVB)-induced
tumour necrosis factor-a (TNFa) apoptotic signalling (28). This
effect was later shown to be mediated through TRIM32 ubiquiti-
nation and destabilization of a pro-apoptotic SUMO-E3 ubiquitin
ligase protein inhibitor of activated STAT Y (PIASy) which exhib-
ited altered intracellular distribution in response to UVB/TNFa-
treatment (29). Whether PIASy is a substrate of TRIM32 in
muscle under normal conditions has yet to be determined.
The aim of this study was to elucidate the cellular role of
TRIM32 and to investigate how TRIM32 mutations might
alter the function of the protein. We have found that TRIM32
is able to bind and ubiquitinate dysbindin, a protein involved
in endosomal–lysosomal trafficking and the genetic aetiology
of schizophrenia (30). The LGMD2H/STM mutants have
impaired ubiquitin ligase activity, were mislocalized in heter-
ologous cells but were able to self-associate. Furthermore, the
common D487N mutant was able to bind to its E2 enzyme but
was not monoubiquitinated under basal conditions. In contrast,
no biochemical differences between wild-type TRIM32 and the
BBS11-associated P130S mutant were found. Our data suggest
that TRIM32 may be a regulator of dysbindin and highlight
important functional differences between wild-type TRIM32
and the LGMD2H/STM mutants D487N and R394H.
RESULTS
TRIM32 can ubiquitinate dysbindin in heterologous cells
TRIM32 is an E3 ubiquitin ligase composed of several distinct
domains (Fig. 1A). Mutations associated with muscle disease
cluster within the NHL repeats, whereas the BBS11 mutation is
found in the BBOX domain (Fig. 1A). The yeast two-hybrid
system (Y2H) was used to identify potential TRIM32-interacing
proteins from a mouse skeletal muscle cDNA library. This screen
isolated three independent full-length clones encoding the protein
dysbindin. Subsequently, we used the Y2H system to determine
whether the D487N (LGMD2H) and P130S (BBS11) mutants,
generated by site-directed mutagenesis, could interact with dys-
bindin. In yeast, the LGMD2H mutant TRIM32–D487N failed
to interact with dysbindin, whereas a robust interaction
between TRIM32–P130S and dysbindin was found (Fig. 1B).
To ensure that the TRIM32-, D487N- and P130S-LexA fusion
proteins were being expressed at comparable levels, protein
extracts were prepared from each yeast strain and analysed by
western blot using the anti-TRIM32 antibody (Fig. 1C). Charac-
terization of the anti-TRIM32 antibody is shown in Supplemen-
tary Material, Fig. S1A. Each protein was produced at similar
levels in yeast suggesting that the lack of interaction between
the LGMD mutant and dysbindin did not result from reduced
expression of the LGMD mutant bait plasmid.
To confirm the interaction between TRIM32 and dysbindin in
mammalian cells, myc-tagged TRIM32 (and mutants thereof)
and dysbindin were transiently transfected into HEK293T cells.
TRIM32 was immunoprecipitated from cell extracts using the
anti-myc 9E10 antibody. The immune complexes were immuno-
blotted and probed for the presence of dysbindin using the
anti-dysbindin antibody PA3111A (31). Figure 1D shows that
wild-type TRIM32 and all of the mutants [D487N, P130S and
RING mutant (RING-mut)] could co-immunoprecipitate with
dysbindin from HEK293T cell extracts.
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To determine whether TRIM32 could act as an E3 ubiquitin
ligase for dysbindin, various combinations of expression con-
structs encoding TRIM32, TRIM32–D487N, TRIM–P130S,
TRIM32–RING-mut, myc-dysbindin and haemaglutinin
(HA)-ubiquitin were transfected in to HEK293T cells. In
addition to the aforementioned mutants, we also included a
second LGMD2H mutant R394H, which was recently found
in two patients from Southern Italy (19). The RING-mut con-
struct was produced by site-directed mutagenesis changing
three conserved Zn2þ-co-ordinating residues (C21, C40 and
H42) in the RING domain to alanine. These mutations were pre-
dicted to impair the activity of TRIM32 as an ubiquitin ligase.
Transfected cells were lysed under denaturing and reducing
conditions (1% SDS, 10 mM DTT) to prevent polyubiquiti-
nated proteins co-immunoprecipitating with dysbindin. Myc-
dysbindin was immunoprecipitated from the cell extracts
using the 9E10 antibody. Ubiquitinated dysbindin was ident-
ified by immunoblotting immunoprecipitated myc-dysbindin
with the anti-HA antibody. A band corresponding to monoubi-
quitinated dysbindin is detected with both the anti-myc and the
anti-HA antibodies when wild-type TRIM32 is co-expressed
(Fig. 1E). The anti-HA-ubiquitin blot also detects high molecu-
lar weight smearing indicative of polyubiquitination. This
smearing is present in immunoprecipitates from cells expres-
sing both wild-type TRIM32 and the P130S mutant. Interest-
ingly, the intensity of the polyubiquitin smearing was
markedly reduced for the LGMD2H/STM-associated D487N
and R394H mutants, suggesting that these mutations are associ-
ated with impaired ubiquitin ligase activity. As expected,
mutation of the RING domain abolished ubiquitination of dys-
bindin demonstrating that this ubiquitination was solely due to
the function of TRIM32 and not endogenous E3 ubiquitin
ligases. To negate the possibility that the impaired ubiquitin
ligase activity of the D487N and RING-mut was due to the
inherent instability of the protein in transfected cells, we deter-
mined the half-lives of each protein. Wild-type TRIM32 and the
D487N mutant have very similar half-lives (17.7 and 18.5 h,
respectively), whereas P130S and the RING-mut were slightly
more stable (Supplementary Material, Table S1).
In control experiments, we performed the identical ubiquiti-
nation assays using myc-PIASy instead of myc-dysbindin.
PIASy is polyubiquitinated by endogenous E3 ligases in
HEK293T cells in the absence of TRIM32. This ubiquitination
does not increase in the presence of TRIM32 expression
(Fig. 1F). As suggested by Albor et al. (29), one possible
explanation for this finding is that PIASy translocation
from the nucleus occurs only under UVB/TNFa/MG132
treatment, which then permits TRIM32 to modify PIASy.
Without eliciting a stress response, PIASy and TRIM32 are
in different subcellular compartments, where interaction and
ubiquitination would be unlikely to occur (see below and
Fig. 2A).
Synthesis and localization of TRIM32 and dysbindin
in muscle
Western and northern blot analyses of TRIM32 and dysbindin
have shown that each protein is expressed at relatively low
levels in skeletal muscle compared with other tissues such as
the brain (9,20,31) (Supplementary Material, Fig. S1B). To deter-
mine the subcellular localization of TRIM32 and dysbindin in
skeletal muscle, cryosections of guinea pig skeletal muscle
were labelled with rabbit polyclonal antibodies raised against
each protein. Dysbindin immunoreactivity, detected with
PA3111A, could be seen around the Z-line and sarcolemma of
all fibres, as previously reported (Fig. 2) (31). TRIM32 immunor-
eactivity, detected with the 3293 polyclonal antibody (Sup-
plementary Material, Fig. S1), was also found to be
concentrated around the Z-line but was not found at the sarco-
lemma (Fig. 2). Both antigens extended beyond the boundary
of the Z-line. Furthermore, TRIM32 and dysbindin are also
found at the M-line, although the labelling is considerably
weaker compared with the Z-line (Fig. 2). The location of the
Z-line and M-band in each experiment was identified using
monoclonal antibodies that detecta-actinin (Z-line) and myome-
sin (M-band). Pre-absorption of the anti-TRIM32 polyclonal
antibody with the immunising fusion protein abolished labelling
on muscle sections but had no effect on the detection of a-actinin
(Fig. 2). Similarly, pre-absorption of the TRIM32 antibody with
the immunogen blocked specific labelling in transfected cells
over-expressing TRIM32–EYFP (Supplementary Material,
Fig. S2A). Western blotting confirmed the presence of TRIM32
in muscle extracts prepared from different guinea pig muscles
(Supplementary Material, Fig. S3A).
We also determined the levels of TRIM32 and dysbindin
during C2C12 myoblast differentiation. Using quantitative
western blotting, we found that TRIM32 and dysbindin remained
at relatively constant levels during myoblast differentiation over
a 12 days period (Supplementary Material, Fig. S3B). As a posi-
tive control for differentiation, identical cell extracts were probed
with the previously characterized anti-a-dystrobrevin-1 antibody
(a1CT-FP), which detects ana-dystrobrevin-1 isoform known to
be induced during myogenesis (a-dystrobrevinþvr3) (32). These
data suggest that the temporal and spatial distributions of
Figure 1. Dysbindin interacts with TRIM32 in yeast and in vivo. TRIM32 and P130S interact with dysbindin in the Y2H system. (A) Schematic representation of
the domain organization of TRIM32 and location of the disease-associated mutations and the region used for polyclonal rabbit anti-sera generation. (B) TRIM32,
D487N and P130S bait strains were co-transformed with empty prey plasmid (pYesTrp2) or dysbindin prey plasmid. The double transformants were tested for
histidine auxotrophy. The previously characterized b-dystrobrevin (b-db) bait is used as a positive control for the dysbindin interaction. (C) Bait strain protein
lysates were western blotted with the TRIM32 3293 antibody, showing all three DNA-binding LexA-fusions are synthesized at comparable levels in yeast. (D)
TRIM32 and dysbindin interact in mammalian cells. HEK293T cells were transfected with dysbindin and myc-TRIM32, myc-D487N, myc-P130S,
myc-RING-mut. Dysbindin co-immunoprecipitated only in the presence of myc-TRIM32 (or any of the mutants), indicating they form a complex in transfected
cells. (E) Dysbindin is polyubiquitinated by TRIM32. Myc-dysbindin was immunoprecipitated from HEK293T cells expressing HA-ubiquitin and either
TRIM32, D487N, P130S, R394H or RING-mut. Immunoprecipitated dysbindin was probed for the presence of conjugated HA-ubiquitin by western blot. A
high molecular weight smear is seen on the HA blot indicative of polyubiquitination. As expected, the RING mutant is unable to ubiquitinate dysbindin. Inter-
estingly, D487N and R394H have impaired ubiquitin ligase activity towards dysbindin, exemplified by the weaker smearing on the HA blot. (F) Effect of
TRIM32 on the ubiquitination of PIASy. The ubiquitination of PIASy was assessed under identical condition to those for dysbindin as shown in (E).
Co-expression of TRIM32 or TRIM32–D487N had no apparent effect upon the ubiquitination of PIASy. Note that PIASy is modified by endogenous ubiquitin
ligases when expressed in HEK293T cells.
Human Molecular Genetics, 2009, Vol. 18, No. 13 2347
 at A
cquisitions on A
pril 11, 2012
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
TRIM32 and dysbindin are similar in skeletal muscle (Sup-
plementary Material, Fig. S3B).
Immunolocalization of TRIM32, its mutants and dysbindin
in transfected cells
To determine whether TRIM32 and dysbindin are expressed in
the same subcellular compartments, TRIM32–EYFP and dys-
bindin were transfected into COS-7 cells. Following fixation,
the cells were stained for dysbindin and analysed by confocal
microscopy. In agreement with previous reports, TRIM32–
EYFP is seen as cytoplasmic speckles (sometimes referred to
as cytoplasmic bodies), often located around the nucleus
(Fig. 3A). The size and number of the TRIM32 speckles were
dependent on the expression level of the protein, similar to
TRIM5a cytoplasmic bodies (33). Cells expressing low levels
of TRIM32 had a greater number of cytoplasmic bodies with
lower fluorescence intensity, whereas in the cells expressing
higher amounts of TRIM32, the cytoplasmic speckles appear
to coalesce to form larger aggregates that were fewer in
number. These cytoplasmic speckles were also immunoreactive
for ubiquitinated proteins detected with the anti-FK1 mono-
clonal antibody (Fig. 3B). Dysbindin exhibited a diffuse cyto-
plasmic staining pattern, as previously reported (31). In cells
Figure 2. Localization of TRIM32 and dysbindin in skeletal muscle. Longitudinal sections of guinea pig tibialis anterior muscle were stained with the antibodies
3293 (TRIM32), EA-53 (a-actinin), B4 (myomesin) and PA3111A (dysbindin). Primary antibodies were detected using species-specific fluorescent antibody
conjugates (Alexa-488 or rhodamine Red-X). TRIM32 and dysbindin colocalize with a-actinin, suggesting that each protein is found on and around the periphery
of the Z-line. In addition to the Z-line labelling, dysbindin is also found at the sarcolemma and M-band. Pre-incubation of the anti-TRIM32 antibody with the
fusion protein used for immunization blocked labelling in muscle sections but did not interfere with immunoreactivity of a-actinin on the same tissue section.
Scale bar is 20 mm.
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Figure 3. Subcellular distribution of TRIM32, dysbindin and PIASy in COS-7 cells. (A) Co-localization of TRIM32–EYFP and dysbindin in COS-7 cells.
TRIM32–EYFP and dysbindin were transfected into COS-7 cells and stained for dysbindin using PA3111A (red). Dysbindin is diffusely expressed in the cyto-
plasm and nucleus. In addition, dysbindin can be found in aggregates that co-localize with the TRIM32–EYFP fluorescence (arrows), which appear yellow in the
merged image. Myc-tagged PIASy and TRIM32–EYFP were transfected into COS-7 cells and stained for myc using 9E10 (red). PIASy exhibited a nuclear
localization, with TRIM32 residing in cytoplasmic speckles. (B) Localization of TRIM32–EYFP and mutants in COS-7 cells. COS-7 cells were transfected
with TRIM32–EYFP, D487N–EYFP, R394H–EYFP and P130S–EYFP. TRIM32 and P130S form discrete cytoplasmic speckles, whereas D487N and
R394H are predominantly cytoplasmic. TRIM32–EYFP transfected COS-7 cells were stained with FK1, which detects polyubiquitinated proteins (red).
Merging the two images shows that the two antigens predominantly co-localize indicating that TRIM32–EYFP cytoplasmic speckles are associated with poly-
ubiquitinated proteins.
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co-expressing dysbindin and TRIM32, dysbindin immunoreac-
tivity was found in aggregates that also contained TRIM32–
EYFP, suggesting that they are capable of interacting in the
cytoplasm of mammalian cells (Fig. 3A). In control exper-
iments, we confirmed that the apparent co-localization of dys-
bindin and TRIM32 in aggregates in co-transfected cells was
not the result of bleed-through from the different channels fol-
lowing sequential scans on the confocal microscope (Sup-
plementary Material, Fig. S2B).
For comparative purposes, we co-transfected TRIM32–EYFP
and myc-PIASy, a putative TRIM32 substrate. As previously
reported, in the absence of proteasome inhibition and irradiation
PIASy had a nuclear localization that is clearly distinct from
TRIM32 in cytoplasmic speckles (Fig. 3A) (29). We also exam-
ined the subcellular localization of the TRIM32 mutants in
COS-7 cells (Fig. 3B). P130S–EYFP displayed a similar distri-
bution to the wild-type protein, forming distinct cytoplasmic
speckles. In contrast, the LGMD2H/STM-associated D487N–
EYFP and R394H–EYFP mutants exhibited diffuse cytoplasmic
staining, with loss of the characteristic aggregates, which were
only visible in a minority of cells expressing high levels of
the chimera. Similar results were found in C2C12 myoblasts
(Supplementary Material, Fig. S4). The differences in the immu-
nolocalization of the LGMD2H/STM mutants compare with the
wild-type protein are unlikely to be a result of expression differ-
ence because each EYFP–chimera was synthesised at similar
levels (data not shown).
TRIM32 targets dysbindin for degradation
Polyubiquitination is commonly associated with the proteasomal
degradation of certain proteins. Therefore, we examined whether
polyubiquitination of dysbindin by TRIM32 had any effect on its
turnover. Dysbindin was transfected into COS-7 cells with either
wild-type TRIM32 or the RING-mut. Protein synthesis was
blocked with cycloheximide and samples were taken every 5 h.
The levels of protein remaining at each time point were deter-
mined by quantitative western blotting. Figure 4 shows that the
presence of TRIM32 had a destabilising effect on dysbindin
compared with the ubiquitination-defective RING-mut
(Fig. 4B). The western blots show a ladder of lower molecular
weight bands , 50 kDa, which are only present when dysbindin
is co-expressed with TRIM32, but not with the RING-mut (aster-
isk in Fig. 4A). It is possible that these bands represent dysbindin
Figure 4. TRIM32 targets dysbindin for degradation. (A) COS-7 cells were transfected with dysbindin (red) and TRIM32 (green), or dysbindin and the RING mutant
(RING-mut) (all untagged in pCIneo). Protein synthesis was blocked by cycloheximide treatment (50 mg/ml) and samples taken every 5 h. The levels of dysbindin in
lysates was analysed by quantitative western and plotted graphically (B). The presence of TRIM32 destabilizes dysbindin, increasing its turnover relative to
co-expression the RING-mut. Additional bands that might be possible breakdown products of dysbindin can be seen below the main dysbindin band in the presence
of TRIM32, but not the RING-mut (asterisk in A). The error bars show the standard error of the mean from three independent experiments. (C) Knockdown of
TRIM32 in C2C12s by siRNA increases dysbindin levels. C2C12 cells were transfected on consecutive days with either control siRNA (non-targeting pool) or
TRIM32 siRNA. Seventy-two hours after the first transfection lysates were made and levels of TRIM32, dysbindin and tubulin were analysed by quantitative
western blot (WB). TRIM32 and dysbindin levels were normalized to tubulin and plotted as a chart (D). The error bars show the standard error of the mean
from three independent experiments. The TRIM32-specific J-12 duplex achieved 60% knockdown relative to the control siRNA (P , 0.01 in a one-sample
two-tailed t-test). (E) Knockdown of TRIM32 results in a significant increase in dysbindin levels relative to control (P , 0.05 in a one-sample two-tailed t-test).
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breakdown products. Since the RING-mut is able to bind
(Fig. 1C), but not ubiquitinate dysbindin, we conclude that
polyubiquitination of dysbindin by wild-type TRIM32 augments
its degradation.
Our data presented herein point to a potential loss of function
for the LGMD2H/STM TRIM32 mutations D487N and R394H.
To determine whether TRIM32 could regulate dysbindin levels in
vivo, we used small-interfering RNAs (siRNAs) to ‘knockdown’
TRIM32 in C2C12 myoblasts. We first determined the half-life of
endogenous TRIM32 in C2C12 myoblasts. Endogenous TRIM32
appeared to be a relatively stable protein, with a half-life of33 h
(Supplementary Material, Table S1). C2C12 myoblasts were
transfected with either a TRIM32-specific siRNA or non-
targeting control siRNAs. Whole cell lysates taken 72 h post-
transfection were analysed by quantitative immunoblotting.
The TRIM32 siRNA achieved 60% knockdown compared
with the control siRNA duplex (Fig. 4C and D). Conversely, dys-
bindin levels increased by 12% in response to depleted
TRIM32 (Fig. 4C and E). The increase in dysbindin levels follow-
ing TRIM32 knockdown was statistically significant, with a
P-value of , 0.05 in a one-sample two-tailed t-test. Each exper-
iment was performed in quadruplicate. Tubulin levels were unaf-
fected by TRIM32 knockdown. The moderate increase in
endogenous dysbindin levels following siRNA-mediated knock-
down of TRIM32 may be attributable to the partial
co-localization of TRIM32 and dysbindin in transfected cells
(Fig. 3A) or the stability and degree of knockdown of TRIM32
in C2C12 myoblasts.
TRIM32 mutants are not defective in self-association
Having determined that the LGMD2H/STM mutations D487N
and R394H impaired dysbindin ubiquitination, we preceded to
examine the ability of TRIM32 to self-associate. In addition to
dysbindin, TRIM32 was also identified as TRIM32-binding
protein in our Y2H screens of muscle and brain cDNA libraries
(data not shown) indicating the propensity to self-associate. Fur-
thermore, members of the TRIM family can form dimeric or tri-
meric complexes mediated by the tripartite motif (4). Previous
reports have used the Y2H system to show that mutations in
the NHL repeats of TRIM32 impaired self-association (19).
Given the previous dichotomy between results obtained in
yeast and mammalian cells (Fig. 1B and D), we examined the
self-association properties of TRIM32 and its mutants in both
systems. Bait and prey constructs were produced for each
mutant and co-transformed into the reporter yeast strain L40. In
the Y2H system, wild-type TRIM32 and P130S co-transformants
could grow in the absence of histidine, indicating that they self-
associate (Fig. 5A). In contrast, and in agreement with previous
reports, D487N and R394H failed to grow on histidine-deficient
media (19).
In complimentary experiments, co-immunoprecipitation was
used to examine the self-association properties of TRIM32 and
mutants thereof expressed in mammalian cells. The 9E10 anti-
body was used to co-immunoprecipitate the corresponding
EYFP-tagged proteins from HEK293T cells co-transfected
with myc-tagged TRIM32 or mutants thereof. In contrast to
the data obtained in yeast, we found that myc-tagged TRIM32
and each of the mutants co-immunoprecipitated with their
cognate EYFP-tagged construct indicating the propensity for
each protein to self-associate (Fig. 5B). On the basis of the
studies in mammalian cells, it appears that neither the P130S
nor D487N mutations affect the ability of TRIM32 to self-
associate. However, in light of the data from the Y2H system,
it is equally possible that the interaction between dysbindin
and TRIM32 (and the mutants) in HEK cells is mediated by a
‘bridging’ protein or post-translational modification that is not
present in yeast.
In light of the interesting findings of Saccone et al. (19),
showing that an LGMD2H patient was heterozygous for the
R394H allele, we tested the ability of the LGMD2H/STM
mutants to associate with the wild-type protein in yeast and in
mammalian cells. Neither of the mutants was able to interact
with wild-type TRIM32 in the Y2H system (Fig. 5C). In contrast
to the results obtained using yeast, both LGMD2H/STM mutants
immunoprecipitated with wild-type TRIM32 when co-expressed
in HEK293T cells (Fig. 5D). Having found that a wild-type
protein was able to interact with a mutant albeit in heterologous
cells, we tested the ability of the D487N and R394H mutants to
ubiquitinate dysbindin in the presence of wild-type TRIM32.
These experiments were performed as described above;
however, each transfection was spiked with 0.5 mg of a plasmid
encoding TRIM32–EYFP, D487N–EYFP, R394H–EYFP or
RING-mut–EYFP. Each condition was compared with the
ubiquitination-defective RING-mut, since this would represent
a mixture of an active and inactive ubiquitin ligase (Fig. 5E).
Although no gross differences in dysbindin ubiquitination were
observed, it is notable that the levels of monoubiquitinated dys-
bindin were reduced when TRIM32 was co-expressed with the
R394H mutant (asterisks in Fig. 5E). This result was found in
three separate experiments and may reflect the ability of the
R394H mutant to attenuate the activity of wild-type TRIM32.
Finally, we co-expressed the EYFP-tagged LGMD2H/STM
mutants and wild-type TRIM32 in COS-7 cells to determine
whether co-expression of TRIM32 could alter the cytoplasmic
distribution of the mutants that was reported above (Fig. 3B). In
cells expressing myc-TRIM32 and the EYFP-tagged mutants,
both proteins co-localized in cytoplasmic bodies that were remi-
niscent of wild-type TRIM32 (Supplementary Material, Fig. S5).
TRIM32 mutants can bind to their E2-enzyme
in mammalian cells
The RING domain is thought to be responsible for recruiting E2
ubiquitin-conjugating enzymes to RING E3 ligases. It has
recently been suggested that the D487N mutation abolished
the interaction of TRIM32 with the E2 enzyme, UBE2N in
yeast cells (19). Since D487N, and the RING-mut, appeared
to have impaired ubiquitin ligase activity towards dysbindin,
we tested whether these proteins could bind to the E2 enzyme
UbcM3 in mammalian cells. UbcM3 is the mouse orthologue
of human UbcH6, which has previously been shown to be com-
patible with TRIM32 in in vitro ubiquitination assays (27).
TRIM32 and each of the mutants co-immunoprecipitate with
HA-tagged UbcM3 from mammalian cells (Fig. 6). These
data, and those of Gentry et al. (18), highlight potential limit-
ations in the utility of the Y2H system to examine the interaction
between mutant ubiquitin ligases and their associated proteins.
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Impaired monoubiquitination of the D487N mutant
TRIM proteins are thought to function as dimers or trimers (4)
and self-association can lead to autoubiquitination, whereby
an E3 ubiquitin ligase can catalyse ubiquitin conjugation to
its reciprocally bound partner. A higher molecular weight
TRIM32 cross-reactive protein was present in both transfected
cells (see, for example, Figs 1D and 5D) and endogenously in
tissues synthesising the highest levels of the protein (Sup-
plementary Material, Fig. S1B, testes). We postulated that
this protein might correspond to endogenously monoubiquiti-
nated TRIM32. We used a direct biochemical approach to
assay the basal ubiquitination status of TRIM32 and each of
the mutants. Myc-TRIM32 and each of the mutants were tran-
siently transfected into HEK293T cells. The cells were lysed
under denaturing and reducing conditions, and myc-TRIM32
was purified using immunoaffinity chromatography from cell
lysates using 9E10-conjugated Protein G Sepharose beads.
Affinity purified myc-TRIM32 was separated by gel electro-
phoresis and stained with colloidal Coomassie blue. A
strong 72 kDa band corresponding to TRIM32 is present at
similar amounts in all lanes (Fig. 7). A higher molecular
weight band is also present for wild-type TRIM32 and the
P130S mutant (Fig. 7). This upper band is not apparent for
D487N and RING-mut. The upper and lower bands were
excised from the Coomassie stained gel and processed for
Fourier transform ion cyclon resonance mass spectrometry.
Numerous tryptic peptides corresponding TRIM32 were
obtained from bands A1 and A3. In addition to TRIM32,
band A1 yielded multiple peptides obtained from ubiquitin
(Fig. 7). We therefore concluded that the upper band rep-
resents monoubiquitinated TRIM32 and that D487N and the
RING-mut fail to gain this modification. These data are con-
sistent with our finding that the TRIM32 speckles found in
transfected cells also contain ubiquitin. In fact, it appears
that ubiquitin is conjugated directly to TRIM32.
DISCUSSION
The aim of this study was to investigate the cellular function of
TRIM32 and learn more about the molecular defects that underlie
LGMD2H/STM. We used an Y2H approach to identify potential
substrates and regulators of TRIM32. We found that TRIM32
could associate with and ubiquitinate dysbindin augmenting its
degradation. Dysbindin is part of a multiprotein complex
called biogenesis of lysosome-related organelles complex-1
(BLOC-1) that is involved in lysosomal–endosomal trafficking
(34–36). Dysbindin and TRIM32 were both found at the Z-line
in skeletal muscle (Fig. 2). Interestingly, Z-line streaming is a
pathological feature of many muscle diseases including
LGMD2H/STM and was also a found in the mouse Trim32
knockout (20). Although no direct link between dysbindin,
BLOC-1 and muscle disease has been established, dysbindin is
known to participate in the trafficking of proteins to lysosomes
and lysosome-related organelles including some lysosome-
associated membrane proteins (LAMPs) (37,38). Interestingly,
mutations in LAMP-2 cause Danon disease, a complex lysosomal
Figure 6. TRIM32 mutants bind to the E2 ubiquitin-conjugating enzyme
UbcM3. Myc-tagged TRIM32 (and mutants) were immunoprecipitated from
mammalian cells in low stringency RIPA buffer and probed for the presence
of co-immunoprecipitated HA-UbcM3 by western blot using the HA antibody.
All of the TRIM32 variants could immunoprecipitate UbcM3, with the RING
mutant having the most robust interaction.
Figure 5. Self-association properties of TRIM32 and mutants. (A) Y2H-mediated analysis of TRIM32 self-association. Co-transformants containing TRIM32,
D487N, P130S, R394H bait and prey plasmids or empty bait, and prey plasmids were tested for histidine auxotrophy on media lacking histidine containing 5 mM
3-AT. Only wild-type TRIM32 and P130S could self-associate in yeast. In each case, selective and non-selective media are compared. (B) Wild-type TRIM32,
D487N and P130S self-associate in mammalian cells. HEK293T cells were transfected with myc-tagged TRIM32, D487N or P130S and their EYFP-tagged
counterparts. EYFP-tagged proteins are only immunoprecipitated in the presence of the myc-tagged protein, indicating that the myc-tagged and EYFP-tagged
proteins interact. (C) The LGMD2H/STM mutants failed to interact with wild-type TRIM32 in yeast. Bait and preys were co-transformed into yeast as indicated.
TRIM32 is able to self-associate, but failed to interact with either of the LGMD2H/STM mutants. In each case, selective and non-selective media are compared.
(D) Co-immunoprecipitation of wild-type TRIM32 with the LGMD2H/STM mutants, D487N and R394H. HEK293T cells were transfected with the constructed
as indicated. Proteins were immunoprecipitated from the cell extracts using the anti-myc antibody. The anti-GFP antibody was used to detect the
co-immunoprecipitated EYFP-tagged TRIM32. In each case, TRIM32 and the each of the mutants co-immunoprecipitated with myc-tagged wild-type
TRIM32. The EYFP-tagged proteins did not immunoprecipitate in the absence of myc-tagged wild-type TRIM32 demonstrating that non-specific binding to
the beads was not a confounding factor in this experiment. (E) Dysbindin ubiquitination in cells co-expressing wild-type and mutant TRIM32s. Ubiquitination
assays were performed as described above (Fig. 1E). Myc-tagged dysbindin was immunoprecipitated from cells expressing the designated combination of plas-
mids. In each case, wild-type TRIM32 was co-expressed with either 0.5 mg of TRIM32–EYFP, D487N–EYFP, R394H–EYFP or RING-mut–EYFP. Dysbindin
ubiquitination was assessed with the anti-HA antibody as described above. In each reaction, dysbindin is clearly polyubiquitinated by each combination of
TRIM32 and mutant. However in extracts from cells expressing myc-TRIM32 and R394H–EYFP, we consistently found a reduction in the levels of the mono-
ubiquitinated form of dysbindin (asterisk). This change was also detected with the anti-dysbindin antibody (asterisk). Inspection of the lysates revealed that
similar levels of myc-TRIM32, dysbindin and the EYFP-tagged mutants were produced in each transfection.
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myopathy associated with the accumulation of autophagic vacu-
oles in myofibres and impaired lysosomal function (39). Our data
could implicate TRIM32 in the regulation of trafficking in the
lysosomal–endosomal pathway in muscle through the ubiquiti-
nation of proteins such as dysbindin.
Mutations in the human dysbindin gene, DTNBP1, cause a
complex, hypo-pigmentation and bleeding disorder character-
ized by defects in the formation of lysosome-related orga-
nelles, such as melanosomes and platelet-dense granules
(34). A defect in lysosomal–endosomal trafficking may
explain recent evidence linking dysbindin to the psychiatric
disorder schizophrenia (30). A plethora of genetic studies
have linked DTNBP1 variants to an increased susceptibility
to develop schizophrenia (30,40). Furthermore, Talbot et al.
(36) found that dysbindin protein levels are reduced in the
hippocampal formation of schizophrenics relative to age-
matched control. In light of these studies, it is important to
consider that TRIM32-mediated dysbindin ubiquitination
may have a regulatory role, affecting protein trafficking to
endosomes or recycling. These processes are often regulated
by monoubiquitination and K63-linked polyubiquitination
(41). A role for TRIM32 in atypical ubiquitination is further
supported by the study of Saccone et al. (19) who showed
that the ubiquitin ligase E2N, which normally participates in
the formation of lysine-63 linked polyubiquitin chains, may
act as an E2 enzyme for TRIM32.
Using several complimentary techniques, we have demon-
strated that the LGMD2H/STM-associated D487N and
R394H mutations abrogate the ubiquitin ligase activity of
TRIM32. In common with wild-type TRIM32, the D487N
could bind to UbcM3 consistent with current evidence
showing that the RING domain is the main determinant in E2
recruitment (42). Since D487N is able to bind dysbindin, it is
possible that the reduced ubiquitin ligase activity of D487N
results from disruption in protein interactions with other com-
ponents of the ubiquitin–proteasome pathway, and suggests
that the NHL domain is not essential for substrate binding in
this instance. This defect could also be linked to the altered dis-
tribution seen for D487N–EYFP and R394H–EYFP in trans-
fected cells (Fig. 3 and Supplementary Material, Fig. S4) and
the impaired monoubiquitination of D487N (Fig. 7). Since
mutations of the RING domain also resulted in impaired
monoubiquitination, it is likely that this represents an ‘auto-
monoubiquitination’ event that may have a regulatory role.
Molecular modelling of the NHL repeats of TRIM32
suggested that LGMD2H mutations significantly disrupt the
Figure 7. Impaired monoubiquitination of D487N. HEK293T cells were transfected with myc-tagged constructs encoding, TRIM32, TRIM32–D487N,
TRIM32–RING-mut and TRIM32–P130S as indicated. After 24 h, each protein was immunoprecipitated from cell extracts using the 9E10 antibody.
Immune complexes were separated by gel electrophoresis on a 4–20% gradient gel. The gel was stained with colloidal Coomassie blue to visualize protein
bands. Bands A1 and A3 were excised and subjected to FTICR-MS. The table shows the percentage of their amino acid sequence covered by peptides identified
in MS and the number of unique peptides that match this sequence.
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b-propeller structure of the NHL domain (19). This structural
malformation is likely to have a substantial role in the altered
subcellular distribution and function of the LGMD mutant.
In mammalian cells, we found that wild-type and mutant
TRIM32 could self-associate, whereas in yeast, the D487N
and R394H mutants were unable to transactivate expression
of the reporter genes. Since the D487N and R394H mutants
can ubiquitinate dysbindin, albeit to a lesser extent, it
follows that D487N and R394H should be able to bind to dys-
bindin. Although we have not used formal biophysical
methods to show direct binding between dysbindin and
TRIM32 in mammalian cells, our data indicate that the
mutants D487N and R394H are able to associate with dysbin-
din either directly or via an intermediate protein (another
TRIM or TRIM-related protein) co-immunoprecipitating
from transfected cells. It should be noted that neither
TRIM32 nor dysbindin is present in yeast cells suggesting
that their interaction in the Y2H is direct and not mediated
by a third protein. Our findings are similar to those of
Gentry et al. (18), who found that mutations in the NHL
domain of the E3 ubiquitin ligase malin (which causes a
form of myoclonus epilepsy) completely abolished its inter-
action with laforin (the substrate of malin) in the Y2H
system. Despite this, both proteins co-immunoprecipitated
from mammalian cells, with the NHL mutations significantly
impairing the ubiquitin ligase activity of malin towards
laforin (18).
In addition to the self-association properties of TRIM32, we
have also found that wild-type TRIM32 and the LGMD2H/
STM mutants co-localized and co-immunoprecipitate from
cells expressing both proteins (Supplementary Material, Fig. S4
and Fig. 5D). In the case of the R394H mutant, co-expression
with wild-type TRIM32 reduced the level of dysbindin monoubi-
quitination potentially indicating that this mutation may compro-
mise the function of the wild-type protein (Fig. 5E). Interestingly,
Saccone et al. (19) found one LGMD2H patient that was hetero-
zygous for the R394H mutation. It is therefore tempting to specu-
late that an interaction between wild-type and mutant TRIM32
may cause late onset LGMD2H in this patient.
It is striking that all four LGMD2H/STM mutations cluster
within the NHL repeats of TRIM32, yet none of the patients
presented with symptoms of BBS11 and vice versa. BBS11 is
a complex disorder that is associated with an increased inci-
dence of neuropsychiatric disease. For example, BBS patients
are twice as likely to develop schizophrenia compared
with the general population, leading to the suggestion that
BBS genes may themselves be candidate schizophrenia suscep-
tibility genes (43,44). Indeed, recent data suggest disrupted-in-
schizophrenia 1 forms a complex with BBS4 and pericentriolar
material 1 protein at the centrosome, where a number of other
BBS proteins have been found to localize (43). Here, BBS pro-
teins are thought to be involved in the assembly and function of
primary cilia by regulating intracellular transport (22,26).
Although TRIM32 has not been localized to primary cilia,
knockdown of TRIM32 in zebrafish results in defective melano-
some transport (21). Our findings are therefore of particular
interest, since we have characterized a second interaction
between a BBS gene and a schizophrenia susceptibility gene,
both of which appear to have roles in intracellular trafficking.
Some genetic variants in the DTNBP1 gene influence cognitive
performance in the general population and are also associated
with cognitive decline in schizophrenia (45,46). It is therefore
interesting to speculate that the interaction between TRIM32
and dysbindin may play role in the cognitive and neuropsychia-
tric abnormalities in some BBS patients. Although the BBS11
mutation P130S was not defective in dysbindin ubiquitination,
these data may suggest that the P130S mutation disrupts as
yet unidentified aspects of the protein function not affected by
TRIM32 mutations associated with LGMD2H/STM. In
support of this, Chiang et al. (21) found that unlike P130S,
D487N could rescue TRIM32 knockdown BBS phenotypes in
zebrafish.
In summary, we have identified several functional differ-
ences between wild-type and LGMD2H/STM-mutated
TRIM32. These differences affect the localization and poten-
tial regulation of TRIM32 and lead to impaired ubiquitination
of substrates such as dysbindin that we have identified herein.
MATERIALS AND METHODS
Y2H screening
Y2H screening was performed using the Hybrid Hunter system
(Invitrogen). Full-length TRIM32 was amplified by PCR and
cloned into the EcoRI/SalI sites of pHybLex/Zeo (Invitrogen).
The bait strain was created by transforming L40 with TRIM32-
pHybLex/Zeo and used to screen a mouse skeletal muscle
cDNA library (Invitrogen), as previously described (30). Interact-
ing prey plasmids were isolated from yeast using the RPM
yeast plasmid isolation kit (QBiogene) and electroporated into
Escherichia coli XL1 Blue (Stratagene). Plasmids were then
extracted from E. coli using a Qiagen Miniprep kit and sequenced
using a vector primer. For TRIM32 self-association studies,
TRIM32, D487N, R394H and P130S were subcloned into Y2H
bait (pHybLex/Zeo) and prey (pYesTrp2) plasmids and used to
co-transform the yeast strain L40. Co-transformants were
spotted on minimal media lacking tryptophan (þHis) or lacking
histidine and containing 5 mM 3-aminotriazole (-Hisþ5 mM
3-AT). The plates were grown at 308C and examined after 3–5
days.
Antibodies
A PCR fragment encoding amino acids 240–372 of TRIM32
was cloned into pET32b (Novagen) and used to transform
E. coli BL21 (DE3) gold (Stratagene). His-tagged fusion pro-
teins were purified using Talon resin as per manufacturer’s
instructions (Clontech), and used to immunize New Zealand
white rabbits (Sigma-Aldrich). Anti-sera were pre-absorbed
against thioredoxin and affinity purified using proteins
covalently coupled to Sulfolink (Pierce). The anti-dysbindin
antibody PA3111A has been previously described (30).
Commercial antibodies were purchased from Sigma-Aldrich
(a-actinin monoclonal), Covance (HA monoclonal, anti-GFP
monoclonal B34), Biomol (FK1), Rockland immunochemicals
(IR dye 800 anti-mouse IgG), Invitrogen (Alexa Fluor 488 and
680) and Jackson immunochemicals (Rhodamine Red X anti-
rabbit and anti-mouse). Monoclonal antibodies against c-myc
(9E10), a-tubulin (12G10) and anti-myomesin (B4) were
produced from hybridomas and purified and concentrated by
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Protein G Sepharose chromatography (GE Healthcare). The
hybridomas developed by Frankel and Nelsen (12G10) and
Perriard (B4) were obtained from the Developmental Studies
Hybridoma Bank developed under the auspices of the NICHD
and maintained by the University of Iowa, Department of
Biological Sciences, Iowa City, IA 52242, USA.
Expression constructs
Full-length TRIM32, UbcM3 and PIASy were amplified from
a skeletal muscle cDNA library by PCR, and sub-cloned into
pCIneo, pEYFP-N1, pCMV-myc or pCMV-HA. Clones were
verified by full-length sequencing. Mutagenesis was per-
formed using the ‘Quikchange’ mutagenesis kit (Stratagene)
as per manufacturer’s instructions. Dysbindin expression con-
structs have been previously described (30). The HA epitope-
tagged ubiquitin construct was provided kindly by Professor
Dirk Bohmann.
Cell culture and transfection
COS-7, HEK-293T and C2C12 cells were grown in DMEM
supplemented with 10% fetal calf serum and 1% penicillin/
streptomycin. For differentiation, C2C12 cells were placed
in DMEM supplemented with 2% horse serum when cultures
reached 70% confluence. Transfections were carried out using
Fugene-6 (Roche) as per manufacturer’s instructions. For
siRNA, C2C12s were transfected with Lipofectamine 2000
(Invitrogen) on consecutive days and incubated for 72 h.
For time courses, cells were treated with cycloheximide
(50 mg/ml Sigma) 24 h post-transfection, and samples taken
thereafter. Where appropriate, cells were re-treated with
cycloheximide after 24 h.
Immunofluorescence microscopy
Twenty-four hours post-transfection cells grown on coverslips
were rinsed twice with PBS and fixed in methanol at 2208C.
Coverslips were washed twice with PBS and blocked for
20 min in PBS containing 10% fetal calf serum. Antibodies
were added for 45 min at room temperature with agitation.
Primary antibody dilutions were 1:100 (anti-TRIM32 3293),
1:1000 (PA3111A), 1:400 (9E10) and 1:200 (FK1). Coverslips
were washed twice and incubated with anti-Rabbit Rhodamine
Red-X IgG (for PA3111A detection) or anti-rabbit Rhodamine
Red-X IgM (for FK1 detection). Following three washes in
PBS, the coverslips were mounted with Aqua Poly/Mount
(Polysciences Inc.), and analysed using a confocal microscope.
For muscle immunocytochemistry, tibialis anterior muscles
(longitudinal sections) were stretched and fixed in 4% (w/v) par-
aformaldehyde and incubated in 10% (w/v) sucrose for 1 h, 20%
(w/v) sucrose for 1 h and 30% (w/v) sucrose overnight, followed
by embedding. Eight micron sections were prepared and
blocked in 10% (v/v) FCS for 30 min followed by incubation
with primary antibody in TBS. Antibody dilutions used were
1:25 (TRIM32 3293), 1:1000 (a-actinin), 1:10 (PA3111A),
1:100 (myomesin). After washing with TBS, the sections were
incubated with donkey anti-rabbit Alexa 488/Rhodamine
Red-X IgG or goat anti-mouse Alexa-488/Rhodamine Red-X
IgG. For blocking experiments, the anti-TRIM32 3293 antibody
was diluted as described above and pre-absorbed with 50 mg/ml
of fusion protein (thioredoxin–TRIM32) for 1 h at room
temperature prior to use.
Immunoprecipitation and ubiquitination assays
For TRIM32–dysbindin co-immunoprecipitation experiments,
transfected proteins were solubilized from HEK293T cells with
ice-cold RIPA buffer (150 mM NaCl, 50 mM Tris pH 8.0, 1% (v/
v) Triton X-100, 0.5% (w/v) sodium deoxycholate and 1 mM
EDTA). Lysates were pre-cleared with Protein G Sepharose
(Invitrogen) and incubated with 9E10-conjugated beads for
3 h as described previously (47). Immune complexes were
eluted from the beads by boiling in 2 Laemmli sample
buffer/5% b-mercaptoethanol, and analysed by western blot-
ting. For TRIM32–UbcM3 co-immunoprecipitation exper-
iments, immunoprecipitation was performed in low-stringency
buffer (150 mM NaCl, 50 mM Tris pH 8.0, 0.5% (v/v) NP-40
and 1 mM EDTA). For ubiquitination assays, immunoprecipita-
tion was performed as above, except transfected cells were lysed
in denaturing conditions (1% SDS, 50 mM Tris pH 8.0, 10 mM
DTT). For immunoaffinity purification, transfected proteins
were solubilized in RIPA buffer and immunoprecipitated with
9E10. Immune complexes were resolved by gel electrophoresis
using 4–12% Novex pre-cast gradient gels (Invitrogen). The
gel was washed in water to remove SDS and the proteins fixed
by incubating the gel in 7% acetic acid/50% methanol for
15 min. Following washing the bands were visualized by incu-
bating the gel in colloidal Coomassie blue (GelCode Blue,
Pierce) for 2 h followed by destaining in HPLC-grade water.
Mass spectrometry was performed at the Functional Genomics
and Proteomics facility at Birmingham University.
Western blotting
Quantitative western blots were performed as described pre-
viously (47). Briefly, protein extracts were separated by
SDS–PAGE and electroblotted onto nitrocellulose membranes
before probing with primary antibody. After washing, the mem-
branes were incubated with IR fluorophore conjugated second-
ary antibodies, IRDyeTM 800 donkey anti-mouse IgG and Alexa
Fluor 680 goat anti-rabbit IgG. Membranes were then washed
with Tris-buffered saline (TBS), containing 0.1% (v/v)
Tween-20 and rinsed in TBS. Simultaneous two-colour detec-
tion was performed using an Odyssey infrared imaging system
(LI-COR Biosciences, Lincoln, Nebraska). Quantification of
dysbindin and TRIM32 was performed using the Odysseyw
imager application v1.2, normalized to a-tubulin fluorescence
as an internal reference.
Mass spectrometry
Myc-tagged TRIM32 and mutants thereof were transfected into
HEK-293T cells as described above. After 48 h, the cells were
lysed in RIPA buffer and TRIM32 was purified by immunoaffi-
nity chromatography using 9E10-conjugated Protein G Sepha-
rose beads. Purified proteins were resolved by polyacrylamide
gel electrophoresis on 5–20% NuPAGE gels (Novex), fixed
and stained with colloidal Coomassie blue dye (Gelcode,
Pierce). Coomassie stained bands were manually excised and
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processed for mass spectrometry as follows. Proteins in the indi-
vidual gel slices were digested using either a MWG Roboseq
4204 or a QIAGEN 3000 robotic gel handling system (School
of Bioscience, University of Birmingham). Analysis of tryptic
digests was performed on a Thermo Finnigan LTQ-FT with a
capillary high-pressure liquid chromatography system with a
nanospray probe. Five microlitre of sample was run on a long
column (15 cm75 mm C18, 3 mm, 100 A) to separate out pep-
tides. Database searches were performed with MASCOT
(www.matrixscience.com) using the following settings: fixed
modifications, carbamidomethyl (C); variable modifications,
oxidation (M), peptide charge 2þ and 3þ. The data format
was pkl.
RNA interference
C2C12s were transfected with various RNA duplexes using
Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions. Briefly, C2C12 cells were seeded
in 12-well plates (4  104 cells per well) in DMEM
supplemented with 5% fetal calf serum. The following day,
cells were transfected with TRIM32-specific siRNA, 50-GUG
ACUACUUUCUAGCGAAUU and 50-PO4-UUGCGUAGAA
AGUAGUCACUU (Dharmacon) or control siRNA (siCON-
TROL non-targeting siRNA pool, Dharmacon), at a final con-
centration of 33 nM. The growth media was replaced 5 h later.
The transfection protocol was repeated the following day.
Twenty-four hours later (72 h after the first transfection),
cell lysates were prepared by lysing the cells in 100 ml of treat-
ment buffer (75 mM Tris pH 6.8, 4 M urea, 4% SDS, 5%
b-mercaptoethanol).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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